JULIA DINNEN: Open Payments
NPI 1831590413 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,887 in 99 payments from 18 companies in 2025. Trend: 2023 $1,694 · 2024 $2,340 · 2025 $1,887
Food & beverage: $1,887
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 38 | $647 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $367 |
| Janssen Biotech, Inc. | 8 | $164 |
| Gilead Sciences, Inc. | 5 | $102 |
| Ardelyx, Inc. | 4 | $81 |
| Celltrion USA Inc. | 3 | $71 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $71 |
| QOL Medical, LLC | 3 | $63 |
| Ipsen Biopharmaceuticals, Inc | 3 | $56 |
| PFIZER INC. | 3 | $52 |
Products named: ENTYVIO, RINVOQ, SKYRIZI, LINZESS, TREMFYA, IBSRELA, VEGZELMA, XIFAXAN.
Industry payments across VA — which companies pay providers there.
